Login
REGENXBIO Inc. logo

REGENXBIO Inc.

regenxbio.com

What Do They Do?

Licenses its gene-delivery platform to biotechnology and pharmaceutical companies and develops one-time gene therapies for patients with retinal, neuromuscular and neurodegenerative diseases.

How Do They Make Money?

Biotechnology and pharmaceutical partners pay for NAV platform rights; the company earns license fees when it delivers the rights, royalties when licensed products sell, and service fees as it performs development or manufacturing work.

revenue
SegmentShareRevenue
License and royalty
Licensed

92%
FY2022: 100%
Service
Recurring
8.3%

Who Are Their Customers?

Biotechnology and pharmaceutical companies contract directly with REGENXBIO under license and collaboration agreements; named partners include Novartis Gene Therapies and Nippon Shinyaku.

Do Revenues Turn Into Profits?

No. It lost $193.9M in FY2025.

Operating income, FY2025
−95% of revenue
▲ +31% (Loss) vs FY2024 (−$233.3M, −280%)
Net income, FY2025
−114% of revenue
▲ +15% (Loss) vs FY2024 (−$227.1M, −273%)
Free cash flow, FY2025
−74% of revenue
▲ +28% (Loss) vs FY2024 (−$175.6M, −211%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −69%
vs $29.7M in Q3 FY2025
Net income
▲ +34% (Loss)
vs −$61.9M in Q3 FY2025
License and royalty share of revenue vs 79.4% in Q3 FY2025
  • Aug 24, 2026 FDA holds RGX-121; REGENXBIO does not expect to resubmit its application soon The hold followed spine-scan findings without symptoms in five CAMPSIITE participants; the company and its partner are reviewing more scans and follow-up data.

Shrinking. Revenue fell 64% in 4 years, from $470.3M in FY2021 to $170.4M in FY2025, about 22% a year.

Partnered gene therapies The older report names Zolgensma as a partnered program; the latest report also names Itvisma, expanding the platform's partnered product lineup.

Revenue over time
License and royalty Service
$500M$250M$0

Who Do They Compete With?

Competes with 4D Molecular Therapeutics, Amicus Therapeutics, Astellas Pharma, BioMarin Pharmaceutical, Lilly, MeiraGTx, Novartis, Passage Bio, PTC Therapeutics, Roche, Sanofi, Sarepta Therapeutics, Solid Biosciences, Taysha Gene Therapies, Tenaya Therapeutics, Ultragenyx Pharmaceutical, uniQure, Regeneron Pharmaceuticals, Amgen, and Kodiak Sciences

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support